Mutated EGFR-IN-2 |
| Catalog No.GC36667 |
L'EGFR-IN-2 muté (composé 91) est un inhibiteur d'EGFR mutant sélectif extrait du brevet WO2017036263A1, qui inhibe puissamment l'EGFR simple mutant (T790M) et l'EGFR double mutant (y compris L858R/T790M (IC50=<1nM) et ex19del /T790M), et peut également supprimer l'activité de l'EGFR mutant À gain de fonction unique (y compris L858R et ex19del). L'EGFR-IN-2 muté présente une activité anti-tumorale.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2050906-97-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Mutated EGFR-IN-2 (compound 91) is a mutant-selective EGFR inhibitor extracted from patent WO2017036263A1, which potently inhibits single-mutant EGFR (T790M) and double-mutant EGFR (including L858R/T790M (IC50=<1nM) and ex19del/T790M), and can suppress activity of single gain-of-function mutant EGFR (including L858R and ex19del) as well. Mutated EGFR-IN-2 shows anti-tumor antivity[1]. EGFRT790M EGFRL858R EGFRex19del EGFR (L858R/T790M)|<1 nM (IC50)|EGFR (ex19del/T790M)
[1]. 2, 4-di-(nitrogen containing group) substituted pyrimidine compound and preparation method and use thereof.
Average Rating: 5 (Based on Reviews and 40 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *